Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
Xavier Thomas Hospices Civils de Lyon, Hematology, Lyon-Sud Hospital, Pavillon Marcel Bérard, France Abstract: Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the sur...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/89abc1d5f8824785adfdca466fa9eea8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Xavier Thomas Hospices Civils de Lyon, Hematology, Lyon-Sud Hospital, Pavillon Marcel Bérard, France Abstract: Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the surface of leukemia cells in ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, which has shown efficacy in patients with lymphomas, has also shown encouraging activity in relapsed or refractory ALL with a high morphologic and molecular response rate. This article summarizes the current approaches to treating ALL with inotuzumab ozogamicin, based on available data from the literature. Keywords: monoclonal antibody, inotuzumab ozogamicin, CMC-544, acute lymphoblastic leukemia, targeted therapy |
|---|